Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
Key Highlights
- ➤Alamar (ALMR) and GSK launch large-scale proteomic study across five disease areas
- ➤NULISA platform will analyze more than 60,000 serum samples
- ➤Immune 340 and Neuro 220 panels will profile diverse patient cohorts
- ➤Study targets biomarkers for disease progression, subtypes and treatment response
Expert Statements
Robert Scott, Senior vice president, R&D translational sciences at GSK
“Proteomics has emerged as one of the most promising frontiers in precision medicine, and the quality of measurements from Alamar's NULISA platform offer enormous potential.”
Robert Scott, Senior vice president, R&D translational sciences at GSK
“By profiling the proteome at scale across a diverse patient population, we have the potential to shape how we identify patient populations, design clinical trials, and ultimately develop more targeted and effective therapies.”
Robert Scott, Senior vice president, R&D translational sciences at GSK
“This collaboration offers considerable promise to advance our work to discover and develop medicines for patients.”
Dr. Yuling Luo, Founder, chief executive officer and chair of Alamar
“We believe the application of our ultra-sensitive NULISA platform will uncover proteomic patterns that were previously obscured, yielding signatures capable of stratifying patients for precision prevention and treatment at the earliest possible stage.”
Dr. Yuling Luo, Founder, chief executive officer and chair of Alamar
“The insights generated here have the potential inform drug development programs and advance a new standard for what proteomics can deliver in precision medicine.”
Alamar’s NULISAseq™ Immune 340 and NULISAseq™ Neuro 220 panels will be used to investigate disease progression, biological subtypes and treatment response
FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific collaboration with GSK plc (LSE/NYSE: GSK) that will use Alamar’s NULISA™ platform in a large-scale study examining how circulating protein signatures relate to disease progression, biological subtypes and treatment response across respiratory, liver, kidney, neurological and autoimmune conditions. The collaboration intends to generate deep proteomic insights to advance precision prevention, treatment and earlier disease detection in real-world health care settings.
Get started
Create a free account to read the full story.